Kyowa Hakko Kirin Emphasizes Efforts On Kidney Disease With DPP-4
This article was originally published in PharmAsia News
Kyowa Hakko Kirin President Nobuo Hanai announced July 27 at a financial results briefing in Tokyo that the company will continue to provide a wide range of products targeting chronic kidney disease, with focus on renal anemia drugs NESP and ESPO.
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.